Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiwu Lin

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Clinical Lymphoma, Myeloma & Leukemia|September 13, 2024
Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple MyelomaJing Christine Ye, Noa Biran, Sandhya Nair, et al.
Current Medical Research and Opinion|September 15, 2016
Burden of systemic glucocorticoid-related complications in severe asthmaPatrick Lefebvre, Mei Sheng Duh, Marie-Hélène Lafeuille, et al.
Blood Cancer Journal|December 5, 2024
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health databaseS Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON studyChristos Chouaid, Lise Bosquet, Craig Knott, et al.
Atherosclerosis|September 25, 2007
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS StudyHeide Stirnadel, Xiwu Lin, Hua Ling, et al.
Arthritis Research & Therapy|July 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProton Rahman, Philip J Mease, Philip S Helliwell, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2026
Relative Effectiveness of Talquetamab Versus Real-World Physician's Choice Treatment Regimens in Patients With Relapsed/Refractory Multiple Myeloma: Updated Results From an Indirect Treatment ComparisonJing Christine Ye, Noa Biran, Sandhya Nair, et al.
Canadian Respiratory Journal|July 18, 2017
The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, CanadaTam Dang-Tan, Shiyuan Zhang, Ruben V Tavares, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple MyelomaMaría-Victoria Mateos, Ajai Chari, Saad Z Usmani, et al.
Journal of Comparative Effectiveness Research|April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myelomaAmrita Krishnan, Ajay K Nooka, Ajai Chari, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Clinical Lymphoma, Myeloma & Leukemia|September 13, 2024
Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple MyelomaJing Christine Ye, Noa Biran, Sandhya Nair, et al.
Current Medical Research and Opinion|September 15, 2016
Burden of systemic glucocorticoid-related complications in severe asthmaPatrick Lefebvre, Mei Sheng Duh, Marie-Hélène Lafeuille, et al.
Blood Cancer Journal|December 5, 2024
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health databaseS Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2025
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON studyChristos Chouaid, Lise Bosquet, Craig Knott, et al.
Atherosclerosis|September 25, 2007
Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: the GEMS StudyHeide Stirnadel, Xiwu Lin, Hua Ling, et al.
Arthritis Research & Therapy|July 15, 2021
Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisProton Rahman, Philip J Mease, Philip S Helliwell, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2026
Relative Effectiveness of Talquetamab Versus Real-World Physician's Choice Treatment Regimens in Patients With Relapsed/Refractory Multiple Myeloma: Updated Results From an Indirect Treatment ComparisonJing Christine Ye, Noa Biran, Sandhya Nair, et al.
Canadian Respiratory Journal|July 18, 2017
The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, CanadaTam Dang-Tan, Shiyuan Zhang, Ruben V Tavares, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple MyelomaMaría-Victoria Mateos, Ajai Chari, Saad Z Usmani, et al.
Journal of Comparative Effectiveness Research|April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myelomaAmrita Krishnan, Ajay K Nooka, Ajai Chari, et al.
Pageof 3